Why Partner with Laboratorios Gornitz?

Since 1948, we have remained at the forefront of clinical diagnostics, delivering precision, innovation, and unwavering commitment.

We combine state-of-the-art technology, large-scale automation, and an in-house logistics network to ensure efficiency and uncompromising quality at every step.

Processing over 3 million analyses annually with nationwide coverage, we are trusted partners for growing healthcare institutions.

• Our legacy is our foundation.
• Our innovation shapes the future.
• Your trust defines who we are.

Who is our service for?

We deliver high-precision, agile diagnostic services tailored to healthcare
professionals and institutions making critical decisions every day.

• Public and private healthcare providers
needing scale, traceability, and scientific reliability.
• Physicians across specialties who rely on accurate,
timely diagnostics for patient care.
• Local and regional laboratories seeking specialized
analysis, technical support, or operational capacity.
• Clinical researchers and trial sponsors requiring
precision, regulatory compliance, and systematic workflows.
• Patients, both direct and referred,
who trust us for fast, safe, and dependable results.

Where do we operate?

Since 1997, we've built and continuously expanded our proprietary logistics network to guarantee efficient, secure, and accessible sample transport. Today, we cover the entire country, traveling more than 1.5 million kilometers annually.

• 20+ vehicles with satellite tracking (GPS)
• 1.2 million samples transported annually
• Custom-developed mobile app for real-time tracking
• Trained in-house logistics personnel
• Daily sample pickup
• Live tracking of pickups and supply deliveries
• Logistics dashboard for real-time shipment monitoring
• >99% fulfillment rate enabled by operational redundancy
• Temperature-controlled and stability-compliant transport
• Full traceability from collection to result delivery

National & Global Reach

• Outsourced Logistics: In regions outside our direct coverage, we coordinate the optimal transport solution with partner labs.

• Clinical Trials: We collaborate with specialized couriers to ensure secure, compliant global sample shipping.

How does the ELF™ test work?

The Siemens Healthineers ELF™ Test quantifies three key biomarkers of active liver fibrosis:

1• Hyaluronic Acid (HA)
2• Procollagen III N-terminal Peptide (PIIINP)
3• Tissue Inhibitor of Metalloproteinases-1 (TIMP-1)

These markers are algorithmically integrated to generate a standardized ELF™ score.

This score supports clinical decisions in two ways: it helps stage liver fibrosis and assess the risk of progression to cirrhosis and liver-related events (LREs).

ELF™ • Diagnostic Use

Non-invasive fibrosis staging through a blood test.

Fibrosis stage is a well-established predictor of liver-related outcomes in patients with chronic liver disease, regardless of cause.

Numerous studies have demonstrated a strong correlation between ELF™ scores and histological findings in a range of liver conditions, including MASLD/NASH, viral hepatitis, and others — validating its use as a reliable surrogate marker for fibrosis staging.

ELF™ • Prognostic Use

The ELF™ score reflects active and ongoing fibrosis a key driver of liver disease progression.

This enables the test to serve as a powerful prognostic tool, helping healthcare professionals identify patients at higher risk of advancing to cirrhosis or experiencing liver-related complications (LREs).

Important

Thanks to its non-invasive nature and clinically validated performance, the ELF™ Test is ideally suited for routine clinical practice — supporting early intervention, ongoing monitoring, and informed decision-making in at-risk patient populations.

Why ELF™ is ideal for MASLD assessment:
• Suitable for diverse patient populations:
adults, individuals with obesity or type 2 diabetes
• High clinical and economic value
• Enables easier and more frequent risk monitoring
• Non-invasive and accessible: requires only a blood sample
• Broad availability across diagnostic centers

Recommended by Scientific Society Guidelines

Numerous global organizations recognize the clinical relevance of the ELF™ Test:

CLDF (Chronic Liver Disease Foundation): 'Demonstrates strong correlation with fibrosis progression in multiple chronic liver diseases.'

European Association for the Study of the Liver (EASL): 'Recommends ELF™ as a second-line non-invasive marker in patients with MASLD to rule out significant fibrosis (≥F2).'

BSG (British Society of Gastroenterology): 'Suggests ELF™ for intermediate-risk patients as an alternative to biopsy.'

The National Institute for Health and Care Excellence (NICE): 'Recommends ELF™ for evaluating advanced fibrosis in patients diagnosed with MASLD.'

American Association for the Study of the Liver Diseases (AASLD): 'Supports the use of non-invasive scores (NFS, FIB-4) to identify patients with higher likelihood of advanced fibrosis.'

American Diabetes Association (ADA): 'Endorses the use of non-invasive biomarkers to assess fibrosis risk, with specialist referral as needed.'

Could this be my patient?

Obesity, type 2 diabetes, hypertension, and cardiovascular disease are all strongly associated with Metabolic Liver Disease (MASLD) — the hepatic manifestation of metabolic syndrome.

The ELF™ Test, FDA-approved and non-invasive, empowers clinicians to identify patients with NASH and advanced fibrosis (F3 or F4) who are at risk of progressing to cirrhosis or liver-related events.

Unlike traditional diagnostics, ELF™ assesses active fibrosis, offering meaningful prognostic insights rather than simply confirming existing damage.